Summary of findings 2. Summary of findings.

Adjuvant cisplatin/doxorubicin/paclitaxel (CDP) compared with cisplatin/doxorubicin (CD) for women with advanced (stage III/IV) endometrial cancer
Patient or population: women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy Settings: hospital Intervention: CDP Comparison: CD
Outcomes	Relative effect (95% CI)	No of participants (trials)	Quality of the evidence (GRADE)	Comments
PFS (stage III/IV) Median follow‐up 46/47 months	HR 0.90 (0.69 to 1.17)	552 (1)	⊕⊕⊕⊝ moderate	We considered this evidence high quality but downgraded it to moderate, as mature OS data has not yet been published, therefore we cannot exclude other differences in survival risks/benefits.
CI: Confidence interval; HR: Hazard ratio; PFS: Progression‐free survival; CDP: cisplatin/doxorubicin/paclitaxel; CD: cisplatin/doxorubicin.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.